REG - Argent Biopharma Ltd - Director/PDMR Shareholding

Argent BioPharmaAnnouncement

15/10/2024 09:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241015:nRSO2252Ia&default-theme=true

RNS Number : 2252I  Argent Biopharma Limited  15 October 2024

 

15 October 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

PDMR Notification

 

Argent BioPharma Ltd (Argent BioPharma, RGT or the Company), advises of the
following transaction which took place on 15 October 2024 whereby, Roby Zomer
(Argent BioPharma's Managing Director & CEO) was issued 4,000,000 fully
paid ordinary shares in Company at a price of A$0.41 each following the
approval of resolution 1 at a general meeting of shareholders on 1 October
2024.

The notification below, made in accordance with the requirements of the UK
Market Abuse Regulation, provides further detail.

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 (a)  Name                                                            Roby Zomer
 2    Reason for the notification

 (a)  Position                                                        Managing Director and Chief Executive Officer

 (b)  Initial notification/amendment                                  Initial

 (c)  If amendment: reason                                            n/a

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
      Full name of entity                                             Argent BioPharma Ltd

      Legal Entity Identifier Code                                    213800HRE3FQJ6RK4H10

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; (iv) each place
      where transactions have been conducted

 (a)  Description of the financial instrument, type of instrument     Fully Paid Ordinary Shares
 (b)  Identification Code (ISIN)                                      AU0000326647

 (c)  Nature of transaction                                           Shares issued in accordance with the passing of resolution 1 at a general
                                                                      meeting held 1 October 2024.
 (d)  Currency                        Price                                                      Volume                     Total
      AUD                             0.41                                                       4,000,000                  $1,640,000
      Aggregated information
      AUD                             0.41                                                       4,000,000                  $1,640,000
 (e)  Date of transaction                                             15 October 2024

 (f)  Place of transaction                                            Outside a trading venue

 

-Ends-

Authorised for release by the Company Secretary, for further information
please contact:

 Argent BioPharma Limited                                     Argent BioPharma Limited

 Roby Zomer                                                   Rowan Harland

 CEO & Managing Director                                      Company Secretary

 +61 8 6555 2950                                              +61 8 6555 2950

 info@argentbiopharma.com (mailto:info@argentbiopharma.com)   info@argentbiopharma.com (mailto:info@argentbiopharma.com)

About Argent BioPharma

Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an
innovative multidisciplinary drug development Company within the
biopharmaceutical sector.  The Company focuses on multidisciplinary methods
with Nanotechnology, developing multi-target therapies for comprehensive
disease management, especially concerning the Central nervous system (CNS) and
Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGRBDGBUBDGSU